Antimicrobial Susceptibility-guided Therapy for Helicobacter pylori Eradication in patients with Gastric Epithelial Neoplasm

An Antimicrobial Susceptibility-Guided versus Standard Triple Therapy of Helicobacter pylori Infection After Endoscopic Resection of Gastric adenoma and Early Gastric Cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0000805

Enrollment

110

Registered

2013-07-24

Start date

2011-11-28

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Patients treated with triple therapy received pantoprazole 40 mg or lansoprazole 30mg twice daily, amoxicillin 1 g twice daily, and clarithromycin 500 mg twice daily for 7 days. Patients whose

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Consecutive H. pylori-positive patients with GEN were included.

Exclusion criteria

Exclusion criteria: . Exclusion criteria included age: 80 years; prior eradication treatment; severe concomitant diseases; history of allergy to any of the substances used in the study; previous gastric surgery; pregnancy or lactation; chronic use of corticosteroids or non-steroidal anti-inflammatory drugs; and multidrug resistance in the bacterial culture and antimicrobial susceptibility testing (resistance to all of the following drugs: clarithromycin, metronidazole and levofloxacin).

Design outcomes

Primary

Measure	Time frame
H. pylori eradication rates	—

Secondary

Measure	Time frame
antibiotics resistance	—

Countries

Korea, Republic of

Contacts

Public ContactSeon-Young Park

Chonnam National University Hospital

Outcome results